ライフサイエンスコーパス: maltophilia

1 Staphylococcus aureus, and Stenotrophomonas maltophilia).

2 al microbiology laboratories were in fact S. maltophilia.

3 Escherichia hermannii, and Stenotrophomonas maltophilia.

4 reus, A. xylosoxidans, D. acidovorans and S. maltophilia.

5 ident among other respiratory isolates of S. maltophilia.

6 from the emerging pathogen Stenotrophomonas maltophilia.

7 osa and the human pathogen, Stenotrophomonas maltophilia.

8 zinc L1 beta-lactamase from Stenotrophomonas maltophilia.

9 ug resistant human pathogen Stenotrophomonas maltophilia.

10 negative bacilli, including Stenotrophomonas maltophilia.

11 ygenase gene to a megaplasmid in cells of P. maltophilia.

12 d at least one sputum sample positive for S. maltophilia.

13 lin-resistant S. aureus], 2 Stenotrophomonas maltophilia, 1 Klebsiella pneumoniae) and resulted in an

14 and finally, pan-resistant Stenotrophomonas maltophilia (20%).

15 erobacter aerogenes (4.4%), Stenotrophomonas maltophilia (4.3%), Proteus mirabilis (4.0%), Klebsiella

16 dans (100%) followed by MDR Stenotrophomonas maltophilia (46%), MDR Achromobacter xylosoxidans (33%),

17 reus, Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and atypical myc

18 552 genomes of the pathogen Stenotrophomonas maltophilia across 23 sites of the lungs from a patient

19 Pseudomonas aeruginosa, and Stenotrophomonas maltophilia--all major threats to our cancer patients.

20 ring in 2 patients with MDR Stenotrophomonas maltophilia and 2 patients with MDR Achromobacter xyloso

21 To examine the molecular epidemiology of S. maltophilia and A. xylosoxidans in CF, isolates from pat

22 ing can distinguish unique CF isolates of S. maltophilia and A. xylosoxidans, person-to-person transm

23 Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans

24 the Gram negative bacteria Stenotrophomonas maltophilia and Escherichia coli.

25 thogen interaction between C. elegans and S. maltophilia and established a new animal model with whic

26 the opportunistic pathogens Stenotrophomonas maltophilia and Ochrobactrum anthropi were detected in m

27 romobacter xylosoxidans and Stenotrophomonas maltophilia and their antibiotic susceptibility patterns

28 in-resistant P. aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans but was less

29 ae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Enterococcus sp.

30 niae, Enterobacter cloacae, Stenotrophomonas maltophilia, and the Burkholderia cepacia complex (BCC)

31 epresents the first examination of T2S in S. maltophilia, and the data obtained indicate that Xps T2S

32 biology references describe Stenotrophomonas maltophilia as oxidase negative and variable with respec

33 ibitors reverse ceftazidime resistance in S. maltophilia because, unlike clavulanic acid, they do not

34 f CF patients with moderate lung disease, S. maltophilia can be cultured from respiratory tract secre

35 Identification of S. maltophilia can be problematic, and analysis of isolates

36 eruginosa, 14 for A. baumannii, and 2 for S. maltophilia Categorical agreement (CA) was assessed usin

37 ions in the dinuclear active site of the S. maltophilia Class B3 MbetaL move away from each other, b

38 extensively drug-resistant Stenotrophomonas maltophilia clinical isolate expressing L1.

39 The extents of S. maltophilia contamination of environmental sites frequen

40 At the six centers with multiple S. maltophilia culture-positive patients and the seven cent

41 xty-one of 69 CF centers screened had 183 S. maltophilia culture-positive patients, and 46 centers ha

42 ients with > or =10 positive cultures (12 S. maltophilia cultures, 15 A. xylosoxidans cultures) had s

43 sequencing for identification and, unlike S. maltophilia, demonstrated susceptibility to most antibio

44 uginosa, the hazard ratio associated with S. maltophilia detection was 0.89 (95% confidence interval,

45 sted their utility to accurately identify S. maltophilia directly from sputum.

46 Recovery of SCV S. maltophilia from the sputum of CF patients has implicati

47 P. aeruginosa, live E. aerogenes, or live S. maltophilia gave good recovery of cysts.

48 maltophilia, those patients positive for S. maltophilia had the following baseline characteristics b

49 the opportunistic pathogen Stenotrophomonas maltophilia has been determined at 1.7 A resolution by t

50 ic sarcosine oxidase (TSOX) from Pseudomonas maltophilia has been determined at 1.85 A resolution.

51 S. maltophilia has been isolated in association with nemato

52 SXT-resistant S. maltophilia has been reported, but the mechanism of resi

53 Stenotrophomonas maltophilia has recently emerged as an important nosocom

54 Although patients with CF who acquire S. maltophilia have more advanced disease than those who do

55 romobacter xylosoxidans and Stenotrophomonas maltophilia have similar posttransplant survival as comp

56 Nutritional studies of SCV S. maltophilia have suggested auxotrophy in hemin, methioni

57 tility of the SS-PCR to directly identify S. maltophilia in sputum was examined.

58 rs to be important in the pathogenesis of S. maltophilia infection as less than 20% of TNFR1 null mic

59 as the inflammatory response elicited by S. maltophilia infection.

60 plus aztreonam as combination therapy for S. maltophilia infections and confirm that aztreonam-like b

61 allo-beta-lactamase L1 from Stenotrophomonas maltophilia is a dinuclear Zn(II) enzyme that contains a

62 Stenotrophomonas maltophilia is a gram-negative bacterium that has been c

63 Stenotrophomonas maltophilia is a Gram-negative bacterium that is among t

64 Stenotrophomonas maltophilia is a multiple-antibiotic-resistant opportuni

65 Stenotrophomonas maltophilia is a ubiquitous bacterium and an emerging no

66 Stenotrophomonas maltophilia is an emerging opportunistic pathogen that p

67 Stenotrophomonas maltophilia is an emerging, opportunistic nosocomial pat

68 S. maltophilia is highly resistant to most antibiotics, wit

69 The Gram-negative bacterium Stenotrophomonas maltophilia is increasingly identified as a multidrug-re

70 metallo-beta-lactamase from Stenotrophomonas maltophilia is unique among this class of enzymes becaus

71 romobacter xylosoxidans and Stenotrophomonas maltophilia, is poorly characterized.

72 ngosepticum isolates, and 1 Stenotrophomonas maltophilia isolate) producing IMP-1, IMP-1-like, IMP-18

73 We found that a local S. maltophilia isolate, JCMS, is more virulent than the oth

74 te, JCMS, is more virulent than the other S. maltophilia isolates (R551-3 and K279a) tested.

75 ulted in amplification of a band from all S. maltophilia isolates and was uniformly negative for all

76 that can rapidly and accurately identify S. maltophilia isolates and which can be used for the direc

77 veloped and tested against a panel of 112 S. maltophilia isolates collected from diverse geographic l

78 s of suspected small-colony-variant (SCV) S. maltophilia isolates from the sputa of five CF patients

79 SCV S. maltophilia isolates were the only S. maltophilia isolates in these cultures, and none were cl

80 Analysis of a collection of 766 S. maltophilia isolates indicated that approximately 20% ar

81 Respiratory and nonrespiratory S. maltophilia isolates were highly immunostimulatory and e

82 The SCV S. maltophilia isolates were the only S. maltophilia isolat

83 The S. maltophilia isolates were weakly invasive, and low-level

84 baumannii isolates, and 11 Stenotrophomonas maltophilia isolates.

85 i, Serratia marcescens, and Stenotrophomonas maltophilia isolates.

86 ficantly differentially expressed between S. maltophilia JCMS and avirulent bacteria (Escherichia col

87 ken together, these findings suggest that S. maltophilia JCMS evades the pathogen resistance conferre

88 However, S. maltophilia JCMS is virulent to normally pathogen-resist

89 ic bacteria also play a role in combating S. maltophilia JCMS.

90 aride lyase (Smlt1473) from Stenotrophomonas maltophilia k279a, which exhibited significant activity

91 ta-lactam hydrolysis by the Stenotrophomonas maltophilia L1 metallo-beta-lactamase.

92 be P. aeruginosa (n = 10), Stenotrophomonas maltophilia (n = 1), and Burkholderia cepacia (n = 1).

93 as maltophilia (n = 5), MDR Stenotrophomonas maltophilia (n = 26), and CF patients without Achromobac

94 3), Serratia spp. (n = 10), Stenotrophomonas maltophilia (n = 43), Sphingobacterium spp. (n = 3), and

95 ans (n = 15), pan-resistant Stenotrophomonas maltophilia (n = 5), MDR Stenotrophomonas maltophilia (n

96 who were older than 6 years of age, were S. maltophilia negative in the first year of enrollment, an

97 with live P. aeruginosa, E. aerogenes, or S. maltophilia offer optimal recovery of Acanthamoeba.

98 ndation Registry, to assess the effect of S. maltophilia on survival.

99 Achromobacter xylosoxidans, Stenotrophomonas maltophilia or Bulkholderia cenocepacia (n = 131).

100 on of Burkholderia cepacia, Stenotrophomonas maltophilia, or Alcaligenes xylosoxidans; however, isola

101 wn to be highly unstable in Stenotrophomonas maltophilia P21 and Pseudomonas putida H2.

102 aminodeoxychorismate synthase activity of S. maltophilia PabB alone revealed that it is virtually ina

103 ss spectral analysis further suggest that S. maltophilia PabB, like Escherichia coli PabB, binds tryp

104 ies exhibited by StmPr1 may contribute to S. maltophilia pathogenesis in the lung by inducing tissue

105 Xps T2S likely plays an important role in S. maltophilia pathogenesis.

106 o antibiotics may select for both the SCV S. maltophilia phenotype and SXT resistance by interference

107 However, FAD in TSOX from Pseudomonas maltophilia (pTSOX) exhibits properties similar to those

108 Thus, we purified StmPr1 from the S. maltophilia strain K279a culture supernatant and evaluat

109 We recently reported that S. maltophilia strain K279a encodes the Xps type II secreti

110 es of the Xps type II secretion system in S. maltophilia strain K279a.

111 ata from this study, we hypothesized that S. maltophilia strain ZL1 was able to convert E1 to amino a

112 To achieve the objective, Stenotrophomonas maltophilia strain ZL1 was used as a model estrogen degr

113 is a multicomponent enzyme from Pseudomonas maltophilia, strain DI-6, that catalyzes the conversion

114 The source of the majority of S. maltophilia strains colonizing the respiratory tracts of

115 confirmed that once established, the SCV S. maltophilia strains persisted.

116 nes xylosoxidans strains, 5 Stenotrophomonas maltophilia strains, and 5 Pseudomonas aeruginosa strain

117 monas aeruginosa strains, 8 Stenotrophomonas maltophilia strains, and 9 isolates belonging to nine ot

118 Pseudomonas maltophilia, Strept, pneumoniae, and P. intermedia were

119 edicated pabA is evident in the genome of S. maltophilia, suggesting that another cellular amidotrans

120 Despite the lack of invasiveness of S. maltophilia, the immunostimulatory properties of this or

121 With the exception of Stenotrophomonas maltophilia, these organisms are infrequently implicated

122 Compared with patients without S. maltophilia, those patients positive for S. maltophilia

123 rain K279a, the first clinical isolate of S. maltophilia to be sequenced, encodes a functional type I

124 penemases are restricted to Stenotrophomonas maltophilia, to a few Bacteroides fragilis, and to rare

125 overall virulence of clinical isolates of S. maltophilia using the well-characterized opportunistic p

126 la, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Vibrio cholerae, and Yersinia enterocolitic

127 oblem, the genetic and molecular basis of S. maltophilia virulence is quite minimally defined.

128 A putative alginate lyase (Smlt1473) from S. maltophilia was heterologously expressed in Escherichia

129 35 home-use nebulizers, and Stenotrophomonas maltophilia was isolated from 4 of 35 home-use nebulizer

130 Stenotrophomonas maltophilia was isolated from the respiratory tracts of

131 e phenotypic switch from wild-type to SCV S. maltophilia was reproducible in vitro by exposure to SXT

132 allo-beta-lactamase L1 from Stenotrophomonas maltophilia was studied using rapid-scan and stopped-flo

133 lues for P. aeruginosa, A. baumannii, and S. maltophilia were 94.1%, 92.7%, and 95.5%, respectively,

134 lues for P. aeruginosa, A. baumannii, and S. maltophilia were 99.5%, 99.2%, and 100%, respectively.

135 Eighty-two isolates of S. maltophilia were cultured from 67 different environmenta

136 The immunostimulatory properties of S. maltophilia were studied in vitro by stimulating airway

137 We compared patients who acquired S. maltophilia with those who did not, using survival analy

138 Stenotrophomonas maltophilia WR-C is capable of forming biofilm on polyst

139 sight into the virulence potential of the S. maltophilia Xps type II secretion system and its StmPr1